9.21

1.07% -0.10

Prothena Corporation Plc (PRTA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PRTA Giù? Forum Previsione

Precedente Chiudi:

$9.31

Aprire:

$9.4

Volume 24 ore:

584.45K

Relative Volume:

1.03

Capitalizzazione di mercato:

$495.80M

Reddito:

$217.25M

Utile/perdita netta:

$-50.92M

Rapporto P/E:

-9.21

EPS:

-1

Flusso di cassa netto:

$-100.85M

1 W Prestazione:

-3.96%

1M Prestazione:

+2.79%

6M Prestazione:

+12.18%

1 anno Prestazione:

-34.54%

Intervallo 1D:

$8.995

$9.54

Intervallo di 1 settimana:

$8.995

$10.27

Portata 52W:

$4.32

$14.34

Prothena Corporation Plc Stock (PRTA) Company Profile

Nome

Prothena Corporation Plc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

011-353-1-236-2500

Indirizzo

77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2

Dipendente

Cinguettio

@ProthenaCorp

Prossima data di guadagno

2025-02-18

Ultimi documenti SEC

PRTA's Discussions on Twitter

Compare PRTA vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PRTA Prothena Corporation Plc	9.21	495.80M	217.25M	-50.92M	-100.85M	-1.00
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-28	Downgrade	BofA Securities	Neutral → Underperform
2025-05-27	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2025-05-27	Downgrade	Jefferies	Buy → Hold
2025-05-27	Downgrade	Oppenheimer	Outperform → Perform
2024-12-20	Iniziato	Chardan Capital Markets	Buy
2024-01-30	Downgrade	BofA Securities	Buy → Neutral
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-04-24	Iniziato	SVB Securities	Outperform
2023-01-27	Iniziato	Piper Sandler	Overweight
2022-11-04	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2022-09-28	Aggiornamento	BofA Securities	Neutral → Buy
2021-11-19	Iniziato	JMP Securities	Mkt Outperform
2021-06-18	Aggiornamento	BofA Securities	Underperform → Neutral
2021-06-08	Reiterato	Oppenheimer	Outperform
2021-05-26	Iniziato	Citigroup	Buy
2021-02-26	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2021-02-12	Aggiornamento	Jefferies	Hold → Buy
2021-02-02	Aggiornamento	BTIG Research	Neutral → Buy
2020-12-07	Iniziato	H.C. Wainwright	Buy
2020-07-09	Aggiornamento	Oppenheimer	Perform → Outperform
2019-11-19	Aggiornamento	Evercore ISI	In-line → Outperform
2018-05-21	Downgrade	Barclays	Equal Weight → Underweight
2018-04-23	Downgrade	Jefferies	Buy → Hold
2018-04-05	Reiterato	Barclays	Overweight
2017-11-20	Downgrade	Wedbush	Outperform → Neutral
2017-09-29	Reiterato	BTIG Research	Buy
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-08-17	Iniziato	Evercore ISI	Outperform
2017-07-11	Iniziato	Jefferies	Buy
2017-04-12	Iniziato	Cantor Fitzgerald	Overweight
2017-04-12	Iniziato	Piper Jaffray	Overweight
2017-03-02	Iniziato	Instinet	Buy
2016-12-21	Iniziato	SunTrust	Buy
2016-11-03	Iniziato	Deutsche Bank	Buy
2016-08-04	Reiterato	Barclays	Overweight
2016-05-13	Iniziato	Barclays	Overweight
2016-02-19	Reiterato	Wedbush	Outperform
2016-01-21	Iniziato	Credit Suisse	Outperform

Mostra tutto

Prothena Corporation Plc Borsa (PRTA) Ultime notizie

Mar 13, 2026

Prothena Corp plc Stock (ISIN: IE00B91XRN20) Under Pressure Amid Biotech Volatility - AD HOC NEWS

Mar 13, 2026

Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Pressure Amid Biotech Volatility - AD HOC NEWS

Mar 13, 2026

Citizens reaffirms Prothena stock rating on Novo Nordisk milestone By Investing.com - Investing.com UK

Mar 13, 2026

Mar 12, 2026

Prothena earns $50M milestone from Novo Nordisk for drug trial - Investing.com Nigeria

Mar 12, 2026

IPO Launch: Will Prothena Corporation plc outperform tech stocks2026 Movers & Weekly High Return Forecasts - baoquankhu1.vn

Mar 12, 2026

Mar 10, 2026

Prothena (NASDAQ:PRTA) Share Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat

Mar 10, 2026

Mar 09, 2026

Discipline and Rules-Based Execution in PRTA Response - Stock Traders Daily

Mar 09, 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related t - PharmiWeb.com

Mar 09, 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe

Mar 09, 2026

Prothena Corporation Plc Receives $50 Million Clinical Milestone Payment From Novo Nordisk - marketscreener.com

Mar 09, 2026

Mar 07, 2026

Is Prothena Corporation plc stock a dividend growth opportunity2025 Buyback Activity & Real-Time Buy Zone Alerts - Naître et grandir

Mar 07, 2026

Mar 05, 2026

Aug Reactions: Is Prothena Corporation plc attractive for institutional investors - baoquankhu1.vn

Mar 05, 2026

Mar 03, 2026

Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution (NASDAQ:PRTA) - Seeking Alpha

Mar 03, 2026

Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade - Finviz

Mar 03, 2026

Mar 02, 2026

Prothena (NASDAQ:PRTA) Shares Up 8.7%Still a Buy? - MarketBeat

Mar 02, 2026

Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Mar 02, 2026

Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of “Hold” by Analysts - Defense World

Mar 02, 2026

Mar 01, 2026

PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 01, 2026

Feb 27, 2026